Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q2 2026 › vs Q2 2025
NewAmsterdam Pharma Co N.V. (NAMS) Q2 2026 vs Q2 2025 (year over year)
NewAmsterdam Pharma Co N.V.'s revenue fell $15.4M (-81%) from $19.1M in Q2 2025 to $3.7M in Q2 2026.
NewAmsterdam Pharma Co N.V., Q2 2026: revenue $3.7M (-81% year over year), net loss $64.1M, operating cash flow −$39.2M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.7M | $19.1M | −$15.4M | -81% |
| Other income, net | $729K | $18.3M | −$17.5M | -96% |
| Net loss | $64.1M | $17.4M | $46.8M | +269% |
| Costs & expenses | $68.6M | $54.8M | $13.8M | +25% |
| Operating costs | $68.6M | $54.8M | $13.8M | +25% |
| Research & development | $41.7M | $27.5M | $14.2M | +51% |
| SG&A | $26.9M | $27.3M | −$372K | -1% |
| Operating cash sources | $64.1M | $17.4M | $46.8M | +269% |
| Depreciation & amortization | $59K | $45K | $14K | +31% |
| Share-based compensation | $18.4M | $15.2M | $3.2M | +21% |
| Working capital & other | $6.5M | −$35.5M | $42.0M | — |
| Cash used in operations | $39.2M | $37.7M | $1.5M | +4% |
| Net loss absorbed | $64.1M | $17.4M | $46.8M | +269% |
Questions
How much did NewAmsterdam Pharma Co N.V.'s revenue grow year over year in Q2 2026?
NewAmsterdam Pharma Co N.V.'s revenue fell $15.4M (-81%) from $19.1M in Q2 2025 to $3.7M in Q2 2026.